Atea Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to turn the call over to Janae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed.

Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceutical's third quarter 2023 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateapharma.com. With me today from Atea are our chief executive officer and founder, Dr. John Pierce-Amadosi, Chief Development Officer, Dr. Janet Hammond, Dr. Arantahorga, Chief Medical Officer, Andrea Corcoran, Chief Financial Officer and Executive Vice President of Legal, and our Chief Commercial Officer, John D'Avrica. They will all be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Janaye. Good afternoon, everyone, and thank you for joining us. Since the beginning of the year, we made great progress across our COVID-19 and HCV programs. So as you can see on slide three, for our COVID-19 program, enrollment in Sunrise, our global phase three, reflect the inflection rates occurring globally and the study global footprint. Supported by clinical data, including favorable efficacy, safety, and lack of drug interaction profile of Benipozivir, we are pleased with the progression of Sunrise 3 study and we look forward to several important milestones in 2024. Our goal for this program is to deliver an effective treatment to the millions of patients for whom the current standard of care is not adequate. COVID is here to stay, and the area where there is great vulnerability is the urgent need for additional oral antivirals. We believe that venifosfevir has the potential to address the key limitations of current COVID-19 therapies, including safety and drug-drug interactions. New, safe, and well-tolerated oral therapies are also needed to keep up with the evolution of the virus. The SARS-CoV-2 virus indeed is accumulating mutations with amino acid substitutions faster than any other endemic RNA route. To prevent the emergence of cross resistance, we need a broader and more diversified arsenal of all anti-routes with various distinct mechanism of action. As part of a multi-pronged approach against COVID-19, we continue to also make progress with our discovery program focused on the second generation protease inhibitor that is highly differentiated and has a well-suited clinical profile, and we expect to share an update sometime early next year. For our HCV program, we are very pleased with the substantial progress made in our Phase II combination study of benifosbuvir and rosasvir. We have quickly completed enrollment of the 60 patient leading cohorts, and initial results are expected in early 2024. Our goal for this program is to substantially enhance the current standard of care by offering an eight-week, pan-genotypic, protease-free treatment option for HCV patients. Despite treatment options, indeed, they remain a large, underserved HCV patient population that continues to grow dramatically even in the United States due to the opioid crisis, injection drug use, and HCV reinfection. For both our COVID-19 and HCV program, which are each multi-billion dollar commercial opportunities, we are well capitalized to achieve key inflection points with a cash runway well into 2026. Of September 30th, we add $595.1 million of cash and cash equivalents, and Andrea will go over the details with you. I will now turn the call over to Janet for an update on our COVID-19 program.